$ABUS

$4.29 +$0.09 (2.02%) Live

$ABUS Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 197.8M shares outstanding

Who owns ABUS?

By type of holder

Institutions 70.8% Insiders 29.2% Everyone else 0.0%

Concentration Top 10 holders own 81.7%

Gline Matthew 19.6% · Roivant Sciences Ltd. 15.1%

Institutional ownership

70.8%

+0.5 pts vs last qtr

Institutional holders

174

+7 vs last qtr

Net shares bought

+1.0M

by institutions in Q2 2026

New / sold out

33 / 26

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Goldman Sachs Group Inc +2.4M
Nomura Holdings Inc NEW +1.6M

Biggest sellers in Q2 2026

Morgan Stanley −8.2M
Adage Capital Partners GP, L.L.C. SOLD OUT −2.7M

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Arbutus Biopharma Corp in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2015–FY2025

+321.4%

+17.33% a year

Each share's claim on the business

−76.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $66.4M

over 10 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years53% 3–5 years28% 1–3 years11% Under 1 year8%

Quarterly turnover

12.4%

of institutional shares changed hands

Top 10 managers, median time held

5 years

Super Investors

Investment managers reporting ABUS on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
MS Morgan Stanley	17.7M	8.95%	−8.2M (−31.6%)	≤2021	0.0%
Shares held by quarter Peak holding26.7M (Q4'25) Change over 8 quarters−4.0M Share of the company8.950% Morgan Stanley's full portfolio →
TS Two Seas Capital LP	19.1M	9.65%	+538.0K (+2.9%)	2021	1.8%
Shares held by quarter Peak holding19.1M (Q2'26) Change over 8 quarters+10.7M Share of the company9.650% Two Seas Capital LP's full portfolio →

Morgan Stanley

17.7M

% of company

8.95%

Change vs last qtr

−8.2M (−31.6%)

Held since

≤2021

Two Seas Capital LP

19.1M

% of company

9.65%

Change vs last qtr

+538.0K (+2.9%)

Held since

2021

28 more super investors behind a free account

See every manager holding Arbutus Biopharma Corp, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting ABUS on Form N-PORT; together they hold 17.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VT Vanguard Total Stock Market Index Fund Vanguard Index Funds	$24.2M	5.0M	2.54%	0.00%	June 30, 2026
IR iShares Russell 2000 ETF iShares Trust	$19.7M	4.1M	2.08%	0.02%	June 30, 2026

Vanguard Total Stock Market Index Fund

Vanguard Index Funds

Position value

$24.2M

% of company

2.54%

% of the fund

0.00%

As of

June 30, 2026

iShares Russell 2000 ETF

iShares Trust

Position value

$19.7M

% of company

2.08%

% of the fund

0.02%

As of

June 30, 2026

23 more funds behind a free account

See every fund holding Arbutus Biopharma Corp and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
GM Gline Matthew Insider	38.8M	19.64%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company19.640% Gline Matthew's insider activity →
RS Roivant Sciences Ltd. 5%+ holder 13D · 19.5%	29.9M	15.10%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company15.100% Disclosed stake13D · 19.5% View the 13D/G filing →

Gline Matthew

Insider

38.8M

% of company

19.64%

Change vs last qtr

—

Held since

—

Roivant Sciences Ltd.

5%+ holder13D · 19.5%

29.9M

% of company

15.10%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of Arbutus Biopharma Corp.

Comments